Modular PMA
PMA submission strategy where a manufacturer submits portions of the PMA (modules) sequentially as they become ready, rather than as a single complete application.
Definition
Modular PMA is a PMA submission strategy in which the sponsor agrees with FDA in advance on a defined set of modules, typically Preclinical, Manufacturing, and Clinical, that will be submitted separately as each is completed. FDA reviews each module as it arrives and provides feedback before the next module is filed. When all modules are complete and accepted, FDA closes the modular review and the PMA enters substantive review as a complete application. Modular PMAs are most useful for devices with long clinical study durations, where preclinical and manufacturing data are ready years before clinical data.What this means in practice
Modular PMA shortens the calendar time between final data and approval by parallelizing preparation and review. The trade-off is more upfront planning: the sponsor and FDA must agree on the module shell, contents, and order in a pre-submission meeting. Sponsors should pursue modular PMA only when the savings are material, for small or fast-developing devices, a traditional PMA is often simpler.- •Skipping the pre-submission negotiation of module scope, modules submitted without FDA agreement may be rejected or restarted.
- •Treating modular review as a way to defer hard decisions, FDA may still raise major deficiencies that affect later modules.
- •Underestimating the project management burden, three rounds of FDA review and response require more coordination than a single PMA.
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsFDA's five-way taxonomy for post-approval PMA changes, Panel-Track, 180-Day, Real-Time, Special, and 30-Day Notice, each with distinct content and timing.
FDA's most stringent device marketing application, required for high-risk Class III devices.
Voluntary mechanism to obtain FDA feedback before a formal premarket submission.
Expedited PMA supplement review pathway where FDA and the manufacturer meet to review minor device or labeling changes in real time.
More in Regulatory
· Same categoryFDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.
Two alternative disclosure mechanisms in a 510(k) submission, a Summary is public on FDA's website; a Statement promises to share Safety & Effectiveness info on request.
Formal mechanism to ask FDA whether a product is a device and, if so, its likely classification.
510(k) variant that relies on FDA guidance, special controls, or recognized consensus standards.
Where this term appears across MedTech Terms.
Primary references
3 sources- 1
PMA Modular Review GuidanceVerifiedFDAfda.gov
- 2
European Commission - Medical DevicesVerifiedEuropean Commissionhealth.ec.europa.eu
- 3
IMDRF DocumentsVerifiedIMDRFimdrf.org
Inline markers like [1] jump to the matching reference above.